Patents by Inventor Xiaoyan Zhou

Xiaoyan Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240082306
    Abstract: Provided is a chimeric antigen receptor, comprising an antigen binding region, a transmembrane domain and an intracellular signaling region. The antigen binding region comprises an antibody specifically targeting CD7, and the intracellular signaling region consists of a co-stimulatory domain, a primary signal transduction domain, and a ?C chain or intracellular region thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a pharmaceutical composition thereof, and use of the engineered immune cell/pharmaceutical composition for treating cancers.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 14, 2024
    Applicant: BIOHENG THERAPEUTICS LIMITED
    Inventors: Yali ZHOU, Gong CHEN, Tingting GUO, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
  • Patent number: 11886282
    Abstract: Embodiments of this application provide a recovery method for a terminal device startup failure and a terminal device. The method includes: determining that a failure indication event occurs in a startup process, where the failure indication event is used to indicate a startup failure; determining at least one recovery policy based on a type of the failure indication event and/or a cause of the failure indication event; and performing startup recovery based on the at least one recovery policy.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: January 30, 2024
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Liang Zhang, Dechun Qi, Xiaoyan Zhou, Zhiqiang Li, Liang Yu, Dengzhou Xia, Chunhua Hu, Zhongsheng Yan
  • Publication number: 20240019429
    Abstract: Provided herein are methods of determining binding kinetics of a ligand. In some embodiments, the methods include contacting the ligand with a first surface of a substrate, which first surface comprises an electrically conductive coating and a population of receptors connected to the first surface via one or more linker moieties, wherein the receptors bind, or are capable of binding, to the ligand, applying an alternating current electric field to the substrate to induce the receptors to oscillate proximal to the first surface of the substrate, and detecting changes in oscillation amplitudes of the receptors over a duration. Related receptor oscillator array devices, systems and computer readable media are also provided.
    Type: Application
    Filed: July 10, 2023
    Publication date: January 18, 2024
    Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Shaopeng WANG, Guangzhong MA, Xiaoyan ZHOU
  • Publication number: 20230078935
    Abstract: The present application relates to the field of electronic product heat dissipation component and in particular, relates to a graphene thermally conductive gasket edge-wrapped process and an edge-wrapped graphene thermally conductive gasket. The process steps are: coating a layer of adhesive on the first layer of graphene film, placing the second layer of graphene film on the first layer of graphene film, repeating stacking to the target height, obtaining a graphene film block, punching a plurality of through holes penetrating two surfaces of the graphene film block; threading the carbon fiber through the through holes after coating an adhesive on the surface thereof; slicing along the direction parallel to the thickness direction of the graphene film, to obtain the graphene thermally conductive gasket with a specified thickness; and coating a layer of glue on the peripheral sides of the graphene thermally conductive gasket to form an edge-wrapped layer.
    Type: Application
    Filed: January 20, 2022
    Publication date: March 16, 2023
    Inventors: Yong Cao, Aixiang Sun, Shangqiang Yang, Xichang He, Lanyue Dou, Xiaoyan Zhou
  • Publication number: 20220066862
    Abstract: Embodiments of this application provide a recovery method for a terminal device startup failure and a terminal device. The method includes: determining that a failure indication event occurs in a startup process, where the failure indication event is used to indicate a startup failure; determining at least one recovery policy based on a type of the failure indication event and/or a cause of the failure indication event; and performing startup recovery based on the at least one recovery policy.
    Type: Application
    Filed: September 9, 2021
    Publication date: March 3, 2022
    Inventors: Liang Zhang, Dechun Qi, Xiaoyan Zhou, Zhiqiang Li, Liang Yu, Dengzhou Xia, Chunhua Hu, Zhongsheng Yan
  • Patent number: 11119844
    Abstract: Embodiments provide a recovery method for a terminal device startup failure and a terminal device. The method includes: determining that a failure indication event occurs in a startup process, where the failure indication event is used to indicate a startup failure; determining at least one recovery policy based on a type of the failure indication event and/or a cause of the failure indication event; and performing startup recovery based on the at least one recovery policy.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: September 14, 2021
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Liang Zhang, Dechun Qi, Xiaoyan Zhou, Zhiqiang Li, Liang Yu, Dengzhou Xia, Chunhua Hu, Zhongsheng Yan
  • Publication number: 20190360057
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: June 18, 2019
    Publication date: November 28, 2019
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Publication number: 20190307735
    Abstract: This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.
    Type: Application
    Filed: June 18, 2019
    Publication date: October 10, 2019
    Applicant: MERCK SHARP & DOHME CORP
    Inventors: Jason M. Cox, Lijun Ma, Xiaoyan Zhou, Robin E. Haimbach, Paul J. Coleman, Haihong Zhou, David E. Kelley, Selwyn Aubrey Stoch, Le T. Duong, Maarten Hoek
  • Publication number: 20190294490
    Abstract: Embodiments provide a recovery method for a terminal device startup failure and a terminal device. The method includes: determining that a failure indication event occurs in a startup process, where the failure indication event is used to indicate a startup failure; determining at least one recovery policy based on a type of the failure indication event and/or a cause of the failure indication event; and performing startup recovery based on the at least one recovery policy.
    Type: Application
    Filed: October 25, 2016
    Publication date: September 26, 2019
    Inventors: Liang Zhang, Dechun Qi, Xiaoyan Zhou, Zhiqiang Li, Liang Yu, Dengzhou Xia, Chunhua Hu, Zhongsheng Yan
  • Patent number: 10378058
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: August 13, 2019
    Assignee: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Publication number: 20180110762
    Abstract: This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.
    Type: Application
    Filed: March 24, 2016
    Publication date: April 26, 2018
    Applicant: Merck Sharp & Dohme Corp
    Inventors: Jason M. COX, Lijun MA, Xiaoyan ZHOU, Robin E. HAIMBACH, Paul J. COLEMAN, Haihong ZHOU, David E. KELLEY, Selwyn Aubrey STOCH, Le T. DUONG, Maarten HOEK
  • Patent number: 8850944
    Abstract: A gun safety device on a gun automatically prevents the gun from firing when it is inside a registered area, which includes: a positioning device for determining the geographic position of a gun; a data processing device for identifying whether the gun is located within a registered area by comparing the gun's position with the stored geographic positions of the registered areas, and for generating a disable signal when the gun is identified to be inside a registered area; and a safety seizer operable to prevent the gun from discharging in response to receiving the disable signal from the data processing device. The automatic gun safety device may further include a communication device for communications with external networks. Optionally, the data processing device sends the gun's location to a monitoring center. The practice of this invention will ensure the community safety meanwhile defend the constitutional right of gun ownership.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: October 7, 2014
    Inventor: Xiaoyan Zhou
  • Publication number: 20140202058
    Abstract: A gun safety device on a gun automatically prevents the gun from firing when it is inside a registered area, which includes: a positioning device for determining the geographic position of a gun; a data processing device for identifying whether the gun is located within a registered area by comparing the gun's position with the stored geographic positions of the registered areas, and for generating a disable signal when the gun is identified to be inside a registered area; and a safety seizer operable to prevent the gun from discharging in response to receiving the disable signal from the data processing device. The automatic gun safety device may further include a communication device for communications with external networks. Optionally, the data processing device sends the gun's location to a monitoring center. The practice of this invention will ensure the community safety meanwhile defend the constitutional right of gun ownership.
    Type: Application
    Filed: January 22, 2013
    Publication date: July 24, 2014
    Inventor: Xiaoyan Zhou
  • Publication number: 20140112917
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: October 11, 2013
    Publication date: April 24, 2014
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Publication number: 20120039875
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: July 15, 2011
    Publication date: February 16, 2012
    Applicant: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Patent number: 7981618
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: July 19, 2011
    Assignee: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Publication number: 20110150868
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: November 10, 2010
    Publication date: June 23, 2011
    Applicant: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Patent number: D986608
    Type: Grant
    Filed: July 25, 2021
    Date of Patent: May 23, 2023
    Assignee: Taizhou Erchen Dangjia Baby Products Co., Ltd.
    Inventor: Xiaoyan Zhou
  • Patent number: D1000906
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: October 10, 2023
    Assignee: TAIZHOU GERUITE HOUSEWARE CO., LTD.
    Inventor: Xiaoyan Zhou
  • Patent number: D1019306
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: March 26, 2024
    Inventor: Xiaoyan Zhou